

Generation of a heterozygous SCN5A knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition

Marie Gizon, Laëtitia Duboscq-Bidot, Lina El Kassar, Pierre Bobin, Flavie Ader, Karine Giraud-Triboult, Philippe Charron, Eric Villard, Vincent Fontaine, Nathalie Neyroud

▶ To cite this version:

Marie Gizon, Laëtitia Duboscq-Bidot, Lina El Kassar, Pierre Bobin, Flavie Ader, et al.. Generation of a heterozygous SCN5A knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition. Stem Cell Research, 2022, 60, pp.102680. 10.1016/j.scr.2022.102680. hal-03549731

HAL Id: hal-03549731 https://hal.sorbonne-universite.fr/hal-03549731

Submitted on 31 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Contents lists available at ScienceDirect

Stem Cell Research



journal homepage: www.elsevier.com/locate/scr

Lab Resource: Genetically-Modified Single Cell Line

Generation of a heterozygous *SCN5A* knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition

Marie Gizon^a, Laëtitia Duboscq-Bidot^{a,b}, Lina El Kassar^c, Pierre Bobin^a, Flavie Ader^{a,d,e}, Karine Giraud-Triboult^c, Philippe Charron^{a,f}, Eric Villard^a, Vincent Fontaine^g, Nathalie Neyroud^{a,*}

^a Sorbonne Université, Inserm, Research Unit on Cardiovascular and Metabolic Diseases, UMRS-1166, F-75013 Paris, France

^b APHP, Pitié-Salpêtrière Hospital, F-75013 Paris, France

^c CECS/I-STEM, F-91100 Corbeil-Essonnes, France

^d Molecular and Cellular Cardiogenetic and Myogenetic Functional Unit, Hôpital Pitié Salpétrière, DMU BioGem, APHP-Sorbonne Université, F-75013 Paris, France

^e Département 3, UP de Biochimie, UFR de Pharmacie, Université de Paris, F-75006 Paris, France

^f Referral Center for Hereditary Cardiac Diseases, APHP, Pitié-Salpêtrière Hospital, F-75013 Paris, France

^g iPS Core Facility, Institute of Cardiometabolism and Nutrition (ICAN), F-75013 Paris, France

ABSTRACT

Mutations leading to haploinsufficiency in *SCN5A*, the gene encoding the cardiac sodium channel Na_v1.5 α -subunit, are involved in life-threatening cardiac disorders. Using CRISPR/Cas9-mediated genome edition, we generated here a human induced-pluripotent stem cell (hiPSC) line carrying a heterozygous mutation in exon 2 of *SCN5A*, which leads to apparition of a premature stop codon. SCN5A-clone 5 line maintained normal karyotype, morphology and pluripotency and differentiated into three germ layers. Cardiomyocytes derived from these hiPSCs would be a useful model for investigating channelopathies related to *SCN5A* heterozygous deficiency.

(continued)

1. Resource table

(http://creativecommons.org/licenses/by-nc-nd/4.0/).

		Unique stem cell line identifier	1. ICANi002-A-2
Unique stem cell line identifier	1. ICANi002-A-2 https://hpscreg.eu/cell-line/		https://hpscreg.eu/cell-line/ ICANi002-A-2
	ICANi002-A-2	Cell culture system used	Feeder-free conditions
Alternative name(s) of stem cell line	SCN5A-clone 5	Type of Genetic Modification	Induced frameshift mutation in SCN5A
Institution	Sorbonne Université, Inserm, Research		leading to the apparition of a premature
	Unit on Cardiovascular and Metabolic		stop codon
	Diseases, UMRS-1166, F-75013 Paris,	Associated disease	Brugada syndrome OMIM # 601144
	France		Progressive Familial Heart Block, type IA
Contact information of the reported	Nathalie Neyroud: nathalie.		OMIM # 113900
cell line distributor	neyroud@sorbonne-universite.fr	Gene/locus	SCN5A, 3p22.2
Type of cell line	iPSCs	Method of modification/site-specific	CRISPR/Cas9 induced non-homologous
Origin	Human	nuclease used	end-joining (NHEJ)
Additional origin info (applicable for	Age: 30	Site-specific nuclease (SSN) delivery	Plasmid pX459v2.0-SpCas9-HF1
human ESC or iPSC)	Sex: Male	method	nucleofection
	Ethnicity: Caucasian	All genetic material introduced into the	Reprogramming plasmids pCXLE-hUL,
Cell Source	Skin fibroblasts	cells	pCXLE-hOCT3/4 and pCXLE-hSK
Method of reprogramming	Non-integrative episomal plasmid		(Addgene)
	reprogramming		Genome edition plasmid pX459V2.0-
Clonality	Clonal		SpCas9-HF1 (Addgene) carrying Cas9 and
Evidence of the reprogramming	PCR negative for episomal reprogramming	Amplusic of the muslesse terrested allele	the sgRNA targeting exon 2 of SCN5A
transgene loss (including genomic	plasmid backbones	Analysis of the nuclease-targeted allele	Sequencing of the targeted allele
copy if applicable)		status	
	(continued on next column)		(continued on next page)

* Corresponding author at: UMRS-1166, Faculté de médecine Sorbonne Université, 91 boulevard de l'hôpital, 75013 Paris, France. *E-mail address:* nathalie.neyroud@sorbonne-universite.fr (N. Neyroud).

https://doi.org/10.1016/j.scr.2022.102680 Received 3 December 2021; Accepted 17 January 2022 Available online 19 January 2022 1873-5061/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

Table 1

Characterization and validation.

Classification	Test	Result	Data
Morphology	Brightfield photography	Typical morphology of human pluripotent stem cell	Fig. 1C
Pluripotency status evidence for the described cell line	Qualitative analysis (Immunocytochemistry)	Positive for SOX2, OCT4, NANOG, SSEA-4, TRA-1-60 and TRA-1-81	Fig. 1D
	Quantitative analysis (RT-qPCR)	Positive for SOX2, OCT3/4, NANOG and CRYPTO	Fig. 1E
Karyotype	Karyotype using m-FISH	46XY	Fig. 1B
Genotyping for the desired genomic alteration/allelic status of the gene of	PCR across the edited site	Heterozygous status	Sanger sequencing profiles are shown Fig. 1A
interest	Transgene-specific PCR	Absence of transgene integration	Supplementary_S2
Verification of the absence of random plasmid integration events	PCR amplification of plasmid backbones	Absence of plasmid integration	Supplementary_S2
Parental and modified cell line genetic identity evidence	STR analysis	Homo sapiens (human), 18 loci tested, all matched between lines and donor fibroblasts	STR analysis
Mutagenesis / genetic modification outcome analysis	Sequencing (genomic DNA PCR or RT-PCR product)	1 bp deletion, heterozygous	Sanger sequencing is shown on Fig. 1A
	PCR-based analyses	N/A	N/A
	Western blotting	Western-blot revealed a reduced Nav1.5 protein expression in SCN5A-Clone 5	Fig. 1I
Off-target nuclease analysis	PCR across the top 10 off-target sites	Absence of unexpected variants in the top-10 predicted off-target sites	Supplementary_S1
Specific pathogen-free status	Mycoplasma	Negative	Supplementary_S3
Multilineage differentiation potential	Embryoid body and Scorecard	Differentiation into all three germ layers confirmed by scorecard performed on RNA from embryoid bodies	Fig. 1F
Donor screening (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C	N/A	N/A
Genotype - additional histocompatibility info	Blood group genotyping	N/A	N/A
(OPTIONAL)	HLA tissue typing	N/A	N/A

(continued)

Unique stem cell line identifier 1. ICANi002-A-2 https://hpscreg.eu/cell-line/ ICANi002-A-2 Method of the off-target nuclease PCR /sequencing of 10 off-target sites activity surveillance Name of transgene N/A Eukaryotic selective agent resistance Episomal puromycin resistance in genome (including inducible/gene edition plasmid pX459V2.0-SpCas9-HF1 expressing cell-specific) Inducible/constitutive system details N/A September 2021 Date archived/stock date Cell line repository/bank UMRS-1166-iPS-ICAN repository Ethical/GMO work approvals Original human fibroblasts purchased from PromoCell (Germany) See www.promocell.com/ethics Addgene/public access repository Genome edition plasmid pX459V2.0recombinant DNA sources' SpCas9HF1 was a gift from Yuichiro disclaimers (if applicable) Miyaoka (Addgene plasmid #108293; http://n2t.net/addgene: 108293; RRID: Addgene 108293) Reprogramming plasmid pCXLE-hUL was a gift frome Shinya Yamanaka (Addgene plasmid # 27080; http://n2t.net/ addgene:27080; RRID:Addgene_27080) Reprogramming plasmid pCXLE-hOCT3/ 4-shp53-F was a gift from Shinya Yamanaka (Addgene plasmid # 27077; http://n2t.net/addgene:27077; RRID: Addgene_27077) Reprogramming plasmid pCXLE-hSK was a gift from Shinya Yamanaka (Addgene plasmid # 27078; http://n2t.net/ addgene:27078; RRID:Addgene_27078)

2. Resource utility


Expression and/or function of the cardiac sodium channel Na_v1.5, encoded by *SCN5A*, are impaired in hereditary arrhythmias. The SCN5Aclone 5 cell line was established to provide a relevant model of sodium channelopathies related to *SCN5A* haploinsufficiency and an excellent human cellular tool for drug screening and for developing novel therapy (Table 1).

3. Resource details


The cardiac voltage-gated sodium channel α -subunit Na_v1.5, encoded by *SCN5A*, plays a key role in cardiac excitability, as emphasized by more than 250 pathogenic variants identified in *SCN5A* and related to cardiac arrythmias transmitted as autosomal-dominant traits (Wilde and Amin, 2018). Since animal models have inherent limits due to the fundamental differences in cardiac electrophysiology between mice and humans and because human adult cardiomyocytes are not obtainable, *in vitro* human models are needed to explore cardiac-arrythmia pathophysiology. With the aim to model a deficit in Na_v1.5 in human cells as it is observed in patients affected by some loss-of-function mutations in *SCN5A*, we engineered the hiPSC line SCN5A-clone 5 carrying a heterozygous *SCN5A* mutation, leading to apparition of a premature stop codon and haploinsufficiency, by CRISPR-Cas9 genome edition (Ran et al., 2013) of the control hiPSC line ICAN-403.3 (ICANi002-A in hPSCreg: https://hpscreg.eu/cell-line/ICANi002-A).

The pX459V2.0-SpCas9-HF1 plasmid carrying the Cas endonuclease sequence and a specific guide RNA (sgRNA) targeting the start codon in exon 2 of SCN5A was electroporated in the control hiPSC line to induce non-homologous end-joining (Fig. 1A). After Sanger sequencing, the puromycin-resistant clone SCN5A-clone 5 was selected, harboring the SCN5A heterozygous frameshift mutation Chr3(GRCh38): g.38633263del (NM-198056.2 (SCN5A):c.45del; p.Arg15Serfs*82), generating a premature stop codon at amino-acid 96 of Nav1.5 (Fig. 1A). This genome edition targeting the start codon of SCN5A reproduces the $Scn5a^{+/-}$ murine model (Papadatos et al., 2002). Na_v1.5 expression was analyzed by western-blot and the reduction of the protein expression observed in SCN5A-clone 5 cardiomyocytes confirmed SCN5A deficiency in this hiPSC line (Fig. 1I). The absence of mutations in the predicted top-10 off-target sites was assessed by PCR/sequencing (Supplementary S1) and the non-integration of episomal plasmids was validated by PCR targeted on plasmid backbones (Supplementary S2) (Okita et al., 2011). Short tandem repeat (STR) analysis of 18 loci demonstrated matching genetic identities between SCN5A-clone 5, control hiPSC ICAN-403.3 and donor fibroblasts (STR analysis). M-fish cytogenetic analysis performed on SCN5A-clone 5 showed a normal karyotype (Fig. 1B).

 $SCN5A^{+/-}$ cells exhibited a typical hiPSC morphology, similar to control hiPSCs (Fig. 1C) and were tested negative for mycoplasma



PLURIPOTENCY






Fig. 1. Characterization and differentiation of ICANi002-A-2 line. (A) CRISPR/Cas9 genome edition. (B) Karyotype. (C) Brightfield images of control and edited iPSC lines. (D) Immunostaining and (E) RT-qPCR of pluripotency markers. (F) Scorcard analysis. (G) Percent of Troponin-T positive cells counted by cytometry analysis. (H) Immunostaining of α -actinin (red) and troponin T (green) in cardiomyocytes derived from iPSC lines. (I) Na_v1.5 relative-expression quantification by Western-blot.

(Supplementary_S3). Furthermore, SCN5A-clone 5 hiPSCs expressed nuclear (OCT3/4, SOX2, NANOG) and transmembrane (TRA1-60, TRA1-81, SSEA-4) pluripotency markers, as demonstrated by immunofluorescence staining (Fig. 1D) and by RT-qPCR (OCT3/4, SOX2, NANOG and CRYPTO), which showed expression levels comparable to control hiPSCs (Fig. 1E). In parallel, a scorecard analysis was performed on RNA extracted from embryoid bodies to assess the trilineage differentiation potential of SCN5A-clone 5, showing that the *SCN5A*^{+/-} hiPSCs retained the ability to differentiate spontaneously into all three germ layers with an extinction of pluripotency marker expression (Fig. 1F). Table 2

Reagents details.

Antibodies used for immunocytochemistry, western-blot and flow cytometry:				
Assays	Antibody	Company Cat# and RRID	Condition	
Pluripotency markers	Rabbit anti-OCT4	Biovision-Cliniscience Cat # 3576-100 RRID:	1/200 in 1/10 blocking solution	
(Immunostaining)	D-11: to at COVO	Ab_2167563	1 (200 is 1 (10 b) ships as here	
	Rabbit anti-SOX2	Millipore Cat # AB5603 RRID: AB_2286686	1/200 in 1/10 blocking solutio	
	Rabbit anti-NANOG	Cell signaling Ozyme Cat # 4903S RRID: AB_10559205	1/200 in 1/10 blocking solutio	
	Mouse anti-SSEA4	Santa Cruz Cat #sc21704 RRID: AB_628289	1/100 in 1/10 blocking solutio	
	Mouse anti-TRA-1-60	Millipore Cat # MAB4360 RRID: AB_2119183	1/100 in 1/10 blocking solutio	
	Mouse anti-TRA-1-81	Millipore Cat # MAB4381 RRID: AB_177638	1/100 in 1/10 blocking solutio	
Differentiation markers	Rabbit anti-troponin T	Abcam Cat # ab45932 RRID: AB_956386	1/500 in 1/10 blocking solution	
(Immunostaining)	Mouse anti-α-actinin	Sigma Aldrich Cat # A7811 RRID: AB_476766	1/1000 in 1/10 blocking solution	
Nuclear staining	DAPI	Sigma Aldrich Cat # D9542	1/10000 in 1/10 blocking solution	
Secondary antibodies (Immunostaining)	Alexa fluor 594 chicken anti-rabbit IgG	Thermo Fisher Scientific Cat # A21442 RRID: AB 2535860	1/1000 in 1/10 blocking solution	
(Dylight 488 goat anti-mouse IgG	Bethyl Cat # A90-116D2 RRID: AB_10631770	1/1000 in 1/10 blocking solution	
Mounting media	Dako fluoromount	Dako #S3023	-	
-	Anti-cardiac Troponin T antibody,		1/200 in Incide perm solution	
Flow cytometry	REAfinity [™] APC	Miltenyi Cat # 130-120-543 RRID: AB_2783888	1/200 in Inside perm solution	
	REA control antibody, APC, REAfinity [™]	Miltenyi Cat # 130-113-446 RRID: AB_2733446	1/200 in Inside perm solution	
Primary antibodies (Western-blot)	Rabbit anti-Na _v 1.5	Alomone Labs Cat #ASC-005 RRID: AB_2040001	1/200 in PBS-Tween 0.1%-Mil 5%	
	Mouse anti-GAPDH	Proteintech Cat #60004-1-Ig RRID: AB_2107436	1/10000 in PBS-Tween 0.1%- Milk 5%	
Secondary antibodies (Western-blot)	IR dye 800 donkey anti-rabbit	Li-Cor Biosciences #92632213 RRID: AB_621848	1/10000 in PBS-Tween 0.1%- Milk 5%	
Primers and Oligonucleotides:			a 114	
Assays	Target	Forward and reverse primer (5'-3')	Condition	
sgRNA	SCN5A	5' GGGACTCCCGTGTGAACCTG 3'	-	
Targeted mutation sequencing	SCN5A	5' GAATCAGGCCCATTGTCTGT 3'	Tm 60 °C	
		5' GTGACTCATTTCCCCAGAGC 3'	40 cycles	
			491 pb	
Edition plasmid integration (PCR)	AmpR	5' GCTATGTGGCGCGGTATTAT 3'	Tm 60 °C	
i i i i i i i i i i i i i i i i i i i	I	5' AAGTTGGCCGCAGTGTTATC 3'	35 cycles	
		5 Mid110000000101011110 5	186 pb	
	EDNIA 1		•	
Reprogramming plasmid integration	EBNA1	5' ATCAGGGCCAAGACATAGAGATG 3'	Tm 60 °C	
(PCR)		5' GCCAATGCAACTTGGACGTT 3'	35 cycles	
			61 pb	
Pluripotency markers (qPCR)	SOX2	5' CCCAGCAGACTTCACATGT 3'	Tm 60 °C	
		5' CCTCCCATTTCCCTCGTTTT 3'	40 cycles	
			151 pb	
	NANOG	5' CTCCAACATCCTGAACCTCAGC 3'	Tm 60 °C	
		5' CGTCACACCATTGCTATTCTTCG 3'	40 cycles	
		5 GIGAGAGAIIGGIIIGG 5	115 pb	
	OCT4	5' CCTCACTTCACTGCACTGTA 3'	Tm 60 °C	
	0014			
		5' CAGGTTTTCTTTCCCTAGCT 3'	40 cycles	
			164 pb	
	CRYPTO	5'ACAGAACCTGCTGCCTGAAT 3'	Tm 60 °C	
		5'ATCACAGCCGGGTAGAAATG 3'	40 cycles	
			215 pb	
House-keeping gene (qPCR)	RPL32	5' AGTTCCTGGTCCACAACGTC 3'	Tm 60 °C	
1 00 11 9		5' GTGACTCTGATGGCCAGTTG 3'	40 cycles	
			142 pb	
Off-target analysis (PCR)	OFF-TARGET 1	5' AAAGGTGGGTGGGAATATTTG 3'	Tm 60 °C	
OII-LAISEL AIIAIYSIS (PCK)	OTT-TANGET I			
		5' TCCCGTTGACAGGGATTAAA 3'	35 cycles	
			226 pb	
	OFF-TARGET 2	5' TTCAAGCAAGTGCCAAGTATG 3'	Tm 60 °C	
		5' TGCTCATTCTCCATGGCTTT 3'	35 cycles	
			225 pb	
	OFF-TARGET 3	5' GAGCATTTCCTACACTCGGC 3'	Tm 60 °C	
		5' CCTGTACATGCCTTCCCTCA 3'	35 cycles	
			246 pb	
	OFF-TARGET 4	5' CTGTTTGTTCCCTAAGGCGG 3'	Z40 pb Tm 60 °C	
	OTTIANOEL 4			
		5' GCGTGCAACCTAGATCCTTG 3'	35 cycles	
			198 pb	
	OFF-TARGET 5	5' TTCTGATTGAACACTGCCGC 3'	Tm 60 °C	
		5' AATGGTGTGGGGAGAGGTTGT 3'	35 cycles	
			192 pb	
	OFF-TARGET 6	5' CCACTGCCAATATCACCAGA 3'	Tm 60 °C	
		5' GGGCCGAGACGAATACATAG 3'	35 cycles	
			221 pb	
	OFE TADOFT 7	5' ACCCAGATCATAGGCAGGTG 3'	221 PD	
	OFF-TARGET 7	5' CCTGTATGCTGGGTCCTGTT 3'		
		5 TELETATECTERICTURE 3/		

(continued on next page)

5' CCTGTATGCTGGGTCCTGTT 3'

Table 2 (continued)

Antibodies used for immunocytochemistry, western-blot and flow cytometry:				
Assays	Antibody	Company Cat# and RRID	Condition	
			Tm 60 °C	
			35 cycles	
			207 pb	
	OFF-TARGET 8	5' TGGTGGTTACTCTCTCGGTTG 3'	Tm 60 °C	
		5' CCTCTGCAGGACATCTGGTT 3'	35 cycles	
			206 pb	
	OFF-TARGET 9	5' CCATCCCCTTCCTGGTAGTC 3'	Tm 60 °C	
		5' CTGAGAGGTGACACAGTGGA 3'	35 cycles	
			151 pb	
	OFF-TARGET 10	5' TTCACCCCAGGCCAAAGTAT 3'	Tm 60 °C	
		5' TCTCTTGGAGCATATGAAGGC 3'	35 cycles	
			218 pb	

Cardiogenicity of SCN5A-clone 5 was evaluated after differentiation of hiPSCs in 2D culture according to the protocol based on small molecules modulation of the Wnt/ β -catenin pathway (Lian et al., 2013). Importantly, the edited line efficiently differentiated into beating cardiomyocytes with 90% purity according to FACS quantification (Fig. 1G), showing normal sarcomere morphology, as assessed by immunostaining of α -actinin (red signal) and troponin T (green signal) (Fig. 1H).

4. Materials and methods

4.1. Cell culture and differentiation

hiPSCs were cultured on matrigel-coated plates in mTeSRTM1 (*STEMCELL Technologies*) at 37 °C and 5% CO₂ and manually passaged every 4–6 days. Detection of mycoplasma was performed by *Eurofins genomic* (Mycoplasmacheck).

Human iPSCs were dissociated using Gentle cell reagent (*STEMCELL Technologies*) and plated in mTeSR^{TM1} supplemented with 10- μ M Y-27632 (Biotechne) for 24 h. Cells were then differentiated into cardiomyocytes as previously described (Lian et al., 2013).

4.2. Genome edition

The selected sgRNA targeting *SCN5A* (Table 2) predesigned on https ://genome.ucsc.edu/ was cloned into pX459V2.0-SpCas9HF1 (*Addgene*) and electroporated into control hiPSCs using the Amaxa NucleofectorTM starter kit (*Lonza*). After 48 h of puromycin selection, single clones were picked, expanded and screened by sequencing (*Eurofins genomic*) of PCR products spanning the target site (Table 2).

4.3. Genomic integrity control

The absence of random episomal plasmid integration was achieved by PCR on gDNA using primers designed on vector backbones (Table 2). The 10 first predicted off-target sites from https://genome.ucsc.edu/ were checked by PCR/sequencing (primer sequences in Table 2). SCN5A-clone 5 karyotype was assessed using the m-fish technique by CECS/I-STEM (*Corbeil-Essonnes, France*) on 40 metaphases. Cell identity was checked on gDNA from donor fibroblasts, control iPSC line ICAN-403.3 and SCN5A-clone 5 by short tandem repeat (STR) analysis of 18 loci (*LGC Standards ATCC*).

4.4. Pluripotency characterization

Total RNA was extracted using RNeasy® mini kit (*Qiagen*) and cDNA was synthetized by Superscript II First Strand Synthesis System (*Invitrogen*). Pluripotency gene expression was assessed by RT-qPCR (Table 2) and normalized to RPL32.

For immunostaining, cells were fixed in 4% paraformaldehyde for

10 min at room temperature, permeabilized in blocking solution (PBS 2% BSA, 1% Triton) for 30 min and stained with primary antibodies (Table 2) overnight at 4 °C. Then, cells were washed 3 times with PBS and incubated 1 h with secondary antibodies and DAPI for nuclear staining (Table 2), at room temperature. Images were acquired with an epifluorescence Nikon Eclipse Ti microscope (*NIS Elements software*) on Fig. 1D and with a DeltaVision microscope (*GE Healthcare*) on Fig. 1H.

4.5. Trilineage differentiation

To form embryoid bodies, hiPSCs were passaged using a cell scraper into NuclonTM SpheraTM dishes and cultured in TeSRTM E6 (*STEMCELL Technologies*). Ten days later, RNA was isolated and reverse transcribed. A TaqmanTM hPSC ScorecardTM kit (*Thermo Fisher Scientific*) was used to assess the trilineage differentiation potential, according to manufacturer's instructions.

4.6. Flow cytometry

The single cell suspension obtained using Multi Dissociation kit 3 (*Miltenyi Biotec*) was incubated with a viability marker (*Molecular Probes*) for 30 min at 4 °C. Permeabilization, fixation and labelling with anti-TNNT2 antibody (Table 2) were then conducted following the Inside stain kit protocol (*Miltenyi Biotec*). Samples were processed for FACS analysis on a MACSquant analyser 10, (*Miltenyi Biotec*) and analyzed using the FlowJo software.

4.7. Western-blot

Total proteins were extracted from cardiomyocytes using a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton). After SDS-PAGE electrophoresis on 7%-Tris-acétate gel (*Thermofisher*), proteins were transferred to a nitrocellulose membrane (*Biorad*) before incubation with antibodies (Table 2). Signal was detected using a Li-COR Odyssey Infrared Imaging system (*Licor*).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This work was funded by Inserm. The authors wish to thank the iPS-ICAN facility for technical help.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.

Stem Cell Research 60 (2022) 102680

org/10.1016/j.scr.2022.102680.

References

- Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp, T.J., Palecek, S.P., 2013. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 8 (1), 162–175.
- Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., Shibata, T., Kunisada, T., Takahashi, M.,

Takahashi, J., Saji, H., Yamanaka, S., 2011. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8 (5), 409–412.

- Papadatos, G.A., Wallerstein, P.M.R., Head, C.E.G., Ratcliff, R., Brady, P.A., Benndorf, K., Saumarez, R.C., Trezise, A.E.O., Huang, C.- L.-H., Vandenberg, J.I., Colledge, W.H., Grace, A.A., 2002. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. PNAS 99 (9), 6210–6215.
- Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., 2013. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8 (11), 2281–2308.
- Wilde, A.A.M., Amin, A.S., 2018. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. JACC Clin. Electrophysiol. 4 (5), 569–579.